castration-resistant prostate cancer
Conditions
Interventions
None listed
Sponsors
institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with castration-resistant prostate cancer, as defined by either the treating doctor/physician, or by the definition: prostate cancer that is progressing despite medical or surgical castration (i.e. castrate levels of testosterone (<1,7 nmol/L). If no testosterone has been measured, treatment with surgical castration or medical castration (LHRH-agonists or -antagonists) has to be initiated prior to progression of prostate cancer; 2. Patients diagnosed with CRPC after 01-01-2010 and before 01-01-2016.
Exclusion criteria
Exclusion criteria: Lack of follow up (i.e. a second opinion without treatment (typically 1 or 2 outpatient clinic visits) or a single diagnostic procedure without treatment).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate treatment patterns and outcomes in CRPC in daily practice: 1. Response and adverse events of systemic anti-cancer agents in CRPC (including Progression Free Survival (PFS) and Overall Survival (OS)); 2. Resource use and costs of systemic anti-cancer agents in CRPC; 3. Patient reported outcomes (including health related quality of life) (in side study). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Supportive care use in daily practice (surgery, radiotherapy, radionucleides, bone resorption inhibitors, supportive drugs); 2. Referral patterns and second opinion rate; 3. Reasons for treatment decisions (such as patient preference, comorbidity, age); 4. Variation in subgroups: Geographic regions, type of hospital, age groups, treatment groups. | — |
Contacts
Public ContactM.C.P. Kuppen
Erasmus School of Health Policy & Management, Erasmus University Rotterdam
Outcome results
None listed